XM does not provide services to residents of the United States of America.
W
W

WoltersKluwer

News

Arkema, Flatexdegiro, Mediobanca

EUROPE RESEARCH ROUNDUP-Arkema, Flatexdegiro, Mediobanca Oct 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Flatexdegiro and Mediobanca, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : Berenberg raises to buy from hold * Flatexdegiro AG FTKn.DE : Goldman Sachs raises to buy from neutral * Mediobanca MDBI.MI : Deutsche Bank raises to hold from sell * Orsted ORSTED.CO : Deutsche Bank cuts to hold from buy * Syensqo NV SYENS.
A
A
A
A
A
B
B
B
B
B
C
C
C
C
D
E
G
L
M
M
M
N
O
P
R
S
S
S
U
U
V
W
A
D
S
W

Wolters Kluwer CCH Integrator Announces Strategic Agreement With Oneteam Services Group

BRIEF-Wolters Kluwer CCH Integrator Announces Strategic Agreement With Oneteam Services Group Sept 17 (Reuters) - Wolters Kluwer NV WLSNc.AS : WOLTERS KLUWER CCH INTEGRATOR ANNOUNCES STRATEGIC AGREEMENT WITH ONETEAM SERVICES GROUP Source text for Eikon: ID:nBw95Bhjra Further company coverage: [WLSNc.AS] ( Reuters.Briefs@thomsonreuters.com )
W

Academic publishers face class action over ‘peer review’ pay, other restrictions

Academic publishers face class action over ‘peer review’ pay, other restrictions By Mike Scarcella Sept 13 (Reuters) - A University of California Los Angeles neuroscience professor has sued six major academic journal publishers, claiming in a proposed class action that they violated antitrust law by barring simultaneous submissions to multiple journals and denying pay for “peer review” services.
R
W

German $10 bln publisher IPO is buyout exit test

RPT-BREAKINGVIEWS-German $10 bln publisher IPO is buyout exit test The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Yawen Chen LONDON, Sept 12 (Reuters Breakingviews) - Springer Nature’s fourth attempt at going public will set the bar for buyout barons stuck on the way out. The German academic research publisher on Thursday announced its intention to float in Frankfurt, over a decade after private equity owner BC Partners bought in.
I
R
W

German $10 bln publisher IPO is buyout exit test

BREAKINGVIEWS-German $10 bln publisher IPO is buyout exit test The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Yawen Chen LONDON, Sept 12 (Reuters Breakingviews) - Springer Nature’s fourth attempt at going public will set the bar for buyout barons stuck on the way out. The German academic research publisher on Thursday announced its intention to float in Frankfurt, over a decade after private equity owner BC Partners bought in.
I
R
W

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.